4-furan-3-yl-phenylamine | 936249-47-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-furan-3-yl-phenylamine
• 英文别名: Benzenamine, 4-(3-furanyl)-；4-(furan-3-yl)aniline
• CAS: 936249-47-7
• 化学式: C₁₀H₉NO
• 分子量: 159.188
• InChiKey: NSKKXDBWURWAOW-UHFFFAOYSA-N

物化性质

• 熔点：
  92-93 °C
• 沸点：
  286.8±23.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-furan-3-yl-phenylamine 在 2-双环己基膦-2',6'-二甲氧基联苯 、 盐酸 、 palladium diacetate 、 三乙胺 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-(4-(呋喃-3-基)苯基)-4,4,5,5-四甲基-1,3,2-二氧苯甲醛
  参考文献：
  名称：

  Design and synthesis of boronic acid inhibitors of endothelial lipase

  摘要：

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.043
• 作为产物：
  描述：

  4-硝基苯酚三氟甲基磺酸酯 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate monohydrate 、 palladium on activated charcoal 、 氢气 、 palladium diacetate 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 4-furan-3-yl-phenylamine
  参考文献：
  名称：

  Design and synthesis of boronic acid inhibitors of endothelial lipase

  摘要：

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.043

文献信息

• Identification of novel plasminogen activator inhibitor-1 inhibitors with improved oral bioavailability: Structure optimization of N-acylanthranilic acid derivatives
  作者：Nagahisa Yamaoka、Kenji Murano、Hidehiko Kodama、Akihisa Maeda、Takashi Dan、Tetsuo Nakabayashi、Toshio Miyata、Kanji Meguro

  DOI：10.1016/j.bmcl.2017.11.016

  日期：2018.2

  compounds in which 5-chloroanthranilic acid was bound to a variety of highly lipophilic moieties with appropriate linkers was investigated. As the result it appeared that some of the derivatives possessing aryl- or heteroaryl-substituted phenyl groups in the acyl chain had potent in vitro PAI-1 inhibitory activity. Oral absorbability of typical compounds was also evaluated in rats, and compounds 40,

  通过对N-酰基-5-氯邻氨基苯甲酸衍生物的结构-活性关系研究发现了新型的具有显着改善的口服生物利用度的纤溶酶原激活物抑制剂-1（PAI-1）抑制剂。由于亲脂性N-酰基对于邻氨基苯甲酸衍生物强烈抑制PAI-1似乎很重要，因此研究了其中5-氯邻氨基苯甲酸与各种具有适当连接基的高度亲脂性部分结合的化合物的合成。结果表明，某些在酰基链上具有被芳基或杂芳基取代的苯基的衍生物具有有效的体外PAI-1抑制活性。还评估了大鼠中典型化合物的口服吸收能力，化合物40，55，60和76被选择具有相互不同的化学结构，用于进一步药理评价。
• Identification of Piperidine-3-carboxamide Derivatives Inducing Senescence-like Phenotype with Antimelanoma Activities
  作者：Sangmi Oh、Do Yoon Kwon、Inhee Choi、Young Mi Kim、Ji Young Lee、Jiyoung Ryu、Hangyeol Jeong、Myung Jin Kim、Rita Song

  DOI：10.1021/acsmedchemlett.0c00570

  日期：2021.4.8

  commercially available small-molecule libraries with high-throughput screening and high-content screening image-based technology. Our findings showed an initial hit with the embedded N-arylpiperidine-3-carboxamide scaffold-induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. A focused library containing diversely modified analogues were constructed

  本研究评估了诱导衰老的小分子在治疗黑色素瘤中的潜在用途。我们使用高通量筛选和基于图像的高内涵筛选技术筛选了市售的小分子文库。我们的研究结果表明，嵌入的N -arylpiperidine-3-carboxamide 支架诱导人黑色素瘤 A375 细胞的衰老样表型变化对正常细胞没有严重的细胞毒性。构建并检查了一个包含多种修饰类似物的重点文库，以评估从命中1开始的N-芳基哌啶-3-甲酰胺衍生物的构效关系。这项工作确定了一种具有显着抗增殖活性的新型化合物体外并展示了其中的关键结构部分。
• Microballs Containing Ni(0)Pd(0) Nanoparticles for Highly Selective Micellar Catalysis in Water
  作者：Manisha Bihani、Pranjal P. Bora、Maarten Nachtegaal、Jacek B. Jasinski、Scott Plummer、Fabrice Gallou、Sachin Handa

  DOI：10.1021/acscatal.9b02316

  日期：2019.8.2

  water, which poses a significant hindrance to their application in aqueous synthetic catalysis. To overcome these barriers, ligated Ni(0) nanoparticles (diameter <1 nm) containing a minimum amount of Pd(0) in the microballs formed of amphiphile PS-750-M are developed and applied in the highly selective carbamate cleavage. Selectivity and functional group tolerance are thoroughly investigated. Control

  Ni（0）配合物和纳米颗粒（NPS）在水中都是不稳定的，这极大地阻碍了它们在水性合成催化中的应用。为克服这些障碍，开发了由两亲PS-750-M形成的微球中含有最少Pd（0）的连接的Ni（0）纳米粒子（直径<1 nm），并将其应用于高度选择性的氨基甲酸酯裂解。对选择性和官能团耐受性进行了深入研究。对照实验揭示了纳米催化剂的各个组分的重要性。使用基于脯氨酸的两亲物PS-750-M对于实现微球结构，纳米颗粒的稳定性和所需的催化活性至关重要。一旦形成，就可以将微球分离并保存在环境温度下。X射线光电子能谱对催化剂进行了全面表征，扫描电子显微镜，高分辨率透射电子显微镜，热重分析，红外和循环伏安法。对于选择性催化，Ni和Pd的零氧化态至关重要。在催化剂表征和控制实验的基础上，提出了合理的反应机理。
• INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1
  申请人：Miyata Toshio

  公开号：US20110112140A1

  公开（公告）日：2011-05-12

  The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula. Each symbol is defined as those in the specification.

  本发明涉及一种具有纤溶酶原激活因子抑制剂-1（PAI-1）抑制活性的新化合物，以及以该化合物为活性成分的PAI-1抑制剂。本发明还涉及一种具有抑制PAI-1活性并在预防和治疗与PAI-1活性相关的各种疾病方面有用的药物组合物。新化合物由以下一般公式表示，其中每个符号如规范中所定义。
• 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08258129B2

  公开（公告）日：2012-09-04

  The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are as defined in the disclosure, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了通式（1）中X和R1至R3如公开说明所定义的化合物，适用于治疗因细胞过度或异常增殖而表现出的疾病，并用于制备具有上述特性的药物组合物。